Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Cocrystal Pharma, Inc.

COCPNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Aug 5, 2026Accepted Aug 5, 2026, 4:10 PM EDTFiling CIK 1412486Accession 0001493152-26-036169
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-08-03
Issuer
Cocrystal Pharma, Inc.
Issuer CIK
0001412486
Trading symbol
COCP

Reporting owner 1

Name
FROST PHILLIP MD ET AL
Reporting owner CIK
0000898860
Relationship
Director · 10% owner
Address
4400 BISCAYNE BLVD, MIAMI, FL, 33137-3227

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnershipNature of ownership
Common Stock2026-08-03P · Form 475,000A0.9412[F1]1,983,551IBy Frost Gamma Investments Trust[F2]
Table key
P · Form 4
Purchase on the market or privately
A
Acquired
I
Indirect

Non-derivative holdings

Non-derivative holdings · 1 reported row
SecurityAmount ownedOwnership
Common Stock27,100[F3]D
Table key
D
Direct

Footnotes

F1
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.87 to $0.9499, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence.↩ 1
F2
These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.↩ 1
F3
Includes shares of common stock issuable upon vesting of restricted stock units.↩ 1

Remarks

This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Signature 1

Signed
/s/ Phillip Frost, MD ET AL
Date
2026-08-05

Company context

Cocrystal is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical and clinical stage antiviral compounds for unmet medical needs caused by coronavirus, influenza virus and norovirus.

Current securities

Recent company filings

  1. 10-Q filingNov 16, 2026
  2. SCHEDULE 13D/A - filed by OPKO HEALTH, INC. regarding Cocrystal Pharma, Inc.Nov 6, 2026
  3. Regulation FD DisclosureSep 9, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 18, 2026
  5. Regulation FD DisclosureAug 17, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.